FORT LAUDERDALE, FL — (Marketwired) — 02/09/15 — OmniComm Systems, Inc. (OmniComm) (OTCQB: OMCM), a global leading provider of clinical data management technology, announces the appointment of Mr. Feng Cheng as general manager of OmniComm, China. Mr. Cheng will lead OmniComm–s long-term regional strategy, identifying and developing business expansion and growth initiatives.
Recent market research has estimated that the Asia-Pacific region is poised to grow at CAGR of 19.5% in the next five years, with China a major contributor to growth. The contract research organization (CRO) market in China is expected to grow at CAGR of 15%, fueled by international as well as domestic investment in new drug development.
Supporting this strategic commitment for market expansion in the Chinese drug development market, OmniComm will invest to provide localized service, customer and technical support. OmniComm currently supports five clients in China from a total of 25 clients across the Asia region.
“The Asia region is an important element in OmniComm–s international growth plans,” said Stephen Johnson, president and chief operating officer of OmniComm Systems. “The establishment of a new office and the appointment of Mr. Cheng, will aid us in offering our existing and new customers in China improved service and support and position the company for enhanced sales growth in this key market in Asia.”
Prior to joining OmniComm, Mr. Cheng was director for Asia Pacific business development for Merge Healthcare responsible for growing the e-clinical and electronic data capture (EDC) market in China. Prior to Merge Healthcare, Mr. Cheng spent over twenty years with Vertex Pharmaceuticals and Warner-Lambert in areas of increasing responsibility. Mr. Cheng graduated from the Beijing Institute of Chemical Technology in chemical engineering and earned his Masters of Arts in mathematics and computer science and Masters of Business Administration from Eastern Michigan University.
OmniComm Systems, Inc. is a leading strategic software solutions provider to the life sciences industry. OmniComm is dedicated to helping the world–s pharmaceutical, biotechnology, contract research organizations, diagnostic and device firms, and academic medical centers maximize the value of their clinical research investments. Through the use of innovative and progressive technologies these organizations drive efficiency in clinical development, better manage their risks, ensure regulatory compliance and manage their clinical operations performance. OmniComm provides comprehensive solutions for clinical research with an extensive global experience from over 4,000 clinical trials. For more information, visit .
OmniComm, TrialMaster, TrialOne, and Promasys are registered trademarks of OmniComm Systems, Inc. Other names may be trademarks of their respective owners.
You must be logged in to post a comment Login